anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
People with a history of a substance use disorder or substance dependence. Research suggests that diazepam may increase motivation for alcohol consumption and cravings in some individuals with a history of problematic drinking. People with severe personality disorders, such as borderline personality disorder. Patients from the aforementioned groups are monitored closely during therapy for signs of abuse and the development of dependence. Therapy is recommended to be discontinued if any of these signs are noted. If dependence has developed, therapy is still discontinued gradually to avoid severe withdrawal symptoms. Long-term therapy in such instances is not recommended. People suspected of being dependent on benzodiazepine drugs are gradually tapered off the drug. Withdrawals can be life-threatening, particularly when excessive doses have been taken for extended periods. Therefore, equal prudence is used whether dependence has occurred in therapeutic or recreational contexts. Diazepam is seen as a good choice for tapering for those using high doses of other benzodiazepines since it has a long half-life, thus withdrawal symptoms are tolerable. The process is slow (usually from 14 to 28 weeks) but is considered safe when done appropriately.
== Medical uses == Telisotuzumab vedotin is indicated for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
The prefect of Puno, Benito Laso de la Vega, tried to convince his colleagues in Lampa, Agustín Gamarra from Cuzco and Antonio Gutiérrez de la Fuente from Arequipa, of a project of "microfederalism" or "provincial federation" to separate the south and force the whole country to join the Andean federation of Bolívar. Santa Cruz did everything he could to prevent greater autonomy in the regions and persecute any separatist movement. He removed Laso from his duties and warned the other two. Later, during the Gran Colombian-Peruvian War, Sucre's anti-Peruvian attitudes were denounced, who, to commemorate the triumph of the Gran Columbian army over the Peruvian advance, ordered the construction of a commemorative obelisk on the site where the battle occurred, with an inscription increasing the number of Peruvian soldiers that took part in action and decreasing their own, in the following terms: "The Peruvian army of 8,000 soldiers that invaded the land of their liberators, was defeated by 4,000 braves from Colombia on February 27, 1829." José de la Mar protested the words on the monument, which he considered triumphalist and erroneous. In addition, he complained about the treatment received by the Peruvian dead and prisoners after the battle, with emphasis on the decapitation of the corpse of Pedro Raulet, one of the officers who fell in Tarqui, whose head was nailed to a pike and paraded through the streets of Cuenca.
Sources: en.wikipedia.org
Alongside his collaborators, Karl Piez and George Martin at the National Institute of Health, Gross discovered that collagen was composed of three polypeptide chains. These experiments opened up the field of collagen biology. In the early 1960s, Gross began searching for mechanisms whereby collagen fibers are degraded during tissue remodeling alongside Belgian postdoctoral fellow Charles Lapiere. Gross reasoned that collagenolytic enzymes, which previously had been identified only in bacteria, could be made only when and where they were needed. They looked for collagenase in the medium from tissue implants in culture. Together, they found the enzyme and characterized its mechanism of action and its unique cleavage site. With such colleagues as Martin Tanzer, Utaka Nagai, Andrew Kang, and others, Gross continued studies of mechanisms of collagenolysis, lathyrism, and wound healing. In 1969, Gross was promoted to Professor of Medicine at Harvard Medical School and named Biologist at the Massachusetts General Hospital. Scientists from all over the world worked in Gross's Developmental Biology Laboratory in the Department of Medicine at the Massachusetts General Hospital. Gross continued to make important observations on collagen structure, mechanisms of fibrillogenesis, the role of hyaluronic acid and hyaluronidase in wound healing, embryogenesis and limb regeneration, the origin of corneal ulcers, and control of collagenase production. Gross died at age 96 in Waban, Massachusetts of natural causes
In March 1795, it was reported that the Suffolk had arrived in India after a four-month voyage without a trace of scurvy and with a crew that was healthier than when it set out. The effect was immediate. Fleet commanders clamored also to be supplied with lemon juice, and by June the Admiralty acknowledged the groundswell of demand in the navy and agreed to a proposal from the Sick and Hurt Board that lemon juice and sugar should in future be issued as a daily ration to the crews of all warships. It took a few years before the method of distribution to all ships in the fleet had been perfected and the supply of the huge quantities of lemon juice required to be secured, but by 1800, the system was in place and functioning. This led to a remarkable health improvement among the sailors and consequently played a critical role in gaining an advantage in naval battles against enemies who had yet to introduce the measures. Scurvy was not only a disease of seafarers. The early colonists of Australia suffered greatly because of the lack of fresh fruit and vegetables in the winter. There, the disease was called Spring fever or Spring disease and was described as an often-fatal condition associated with skin lesions, bleeding gums, and lethargy. It was eventually identified as scurvy and the remedies already in use at sea were implemented.
Ueda left Sony in December 2011, although he remained under contract to finish work on The Last Guardian. Around mid-2014, he formed GenDesign (stylized as genDESIGN), made up of former members from his team to help complete development of The Last Guardian. At E3 2015, The Last Guardian was announced for release on October 25, 2016, but was later delayed to December 6, 2016. In September 2018, Ueda revealed that the studio was at the prototyping stage of designing a new game, supported with funding from the investment fund Kowloon Nights. In March 2020, Epic Games announced that they would be fully funding development, with the two companies splitting profits in half. At the 2024 Game Awards the first teaser for the game was revealed, then codenamed "Project Robot". The full title, genATLAS, was revealed at Summer Game Fest 2026, alongside the first full trailer.
Sources: en.wikipedia.org
At constant temperature, the rate of carbon assimilation varies with irradiance, increasing as the irradiance increases, but reaching a plateau at higher irradiance. At low irradiance, increasing the temperature has little influence on the rate of carbon assimilation. At constant high irradiance, the rate of carbon assimilation increases as the temperature is increased. These two experiments illustrate several important points: First, it is known that, in general, photochemical reactions are not affected by temperature. However, these experiments clearly show that temperature affects the rate of carbon assimilation, so there must be two sets of reactions in the full process of carbon assimilation. These are the light-dependent 'photochemical' temperature-independent stage, and the light-independent, temperature-dependent stage. Second, Blackman's experiments illustrate the concept of limiting factors. Another limiting factor is the wavelength of light. Cyanobacteria, which reside several meters underwater, cannot receive the correct wavelengths required to cause photoinduced charge separation in conventional photosynthetic pigments. To combat this problem, Cyanobacteria have a light-harvesting complex called Phycobilisome. This complex is made up of a series of proteins with different pigments which surround the reaction center.
Former Richmond player Kevin Sheedy started as head coach in 1981. Essendon reached the Grand Final in 1983, the first time since 1968. Hawthorn won by a then-record 83 points. In 1984, Essendon won the pre-season competition and completed the regular season on top of the ladder. The club played, and beat, Hawthorn in the 1984 VFL Grand Final to win their 13th premiership — their first since 1965. The teams met again in the 1985 Grand Final, which Essendon also won. At the start of 1986, Essendon were considered unbackable for three successive flags, but a succession of injuries to key players Paul Van der Haar (only fifteen games from 1986 to 1988), Tim Watson, Darren Williams, Roger Merrett and Simon Madden led the club to win only eight of its last eighteen games in 1986 and only nine games (plus a draw with Geelong) in 1987. In July 1987, the Bombers suffered a humiliation at the hands of Sydney, who fell two points short of scoring the then highest score in VFL history. In 1988, Essendon made a rebound to sixth place with twelve wins, including a 140-point thrashing of Brisbane in which they had a record sixteen individual goalkickers. In 1989, they rebounded further to second on the ladder with only five losses and thrashed Geelong in the Qualifying Final. However, after a fiery encounter with Hawthorn ended in a convincing defeat, the Bombers were eliminated by Geelong the following week. In 1990, Essendon finished top of the ladder.
=== Treatment === When noma is detected early, its progression can be rapidly halted through basic hygiene, antibiotics, and improved nutrition. However, its physical effects are permanent and may require oral and maxillofacial surgery or reconstructive plastic surgery to repair. Treatments for noma in the acute stage include penicillin, sulfonamides, and other antibiotics. In all stages of noma, the World Health Organization encourages antibiotics, vitamin A supplements or other nutritional supplements, a high-protein diet, and proper hydration. The World Health Organization recommends using amoxicillin and metronidazole in tandem to treat stage I noma (acute necrotizing gingivitis), along with the use of chlorhexidine and hydrogen peroxide to clean the mouth and gums. For stage II noma (edema phase), stage III noma (acute/gangrenous stage), and stage IV noma (scarring phase), the WHO recommends either one of two therapies. The first therapy includes the concurrent use of amoxicillin, clavulanic acid, gentamicin, and metronidazole. The second option includes the concurrent use of ampicillin, gentamicin, and metronidazole. For both options, chlorhexidine mouthwash is advised. For stage III and IV noma, the use of ketamine, and honey are both given as options for dressing the lesions. Reconstruction is usually very challenging and should be delayed until full recovery (usually about one year following initial intervention).
=== Red algal derived chloroplasts === Secondary chloroplasts derived from red algae appear to have only been taken up only once, which then diversified into a large group called chromists or chromalveolates. Today they are found in the haptophytes, cryptomonads, heterokonts, dinoflagellates and apicomplexans (the CASH lineage). Red algal secondary chloroplasts usually contain chlorophyll c and are surrounded by four membranes. However, chromist monophyly has been rejected, and it is considered more likely that some chromists acquired their plastids by incorporating another chromist instead of inheriting them from a common ancestor. Cryptophytes seem to have acquired plastids from red algae, which were then transmitted from them to both the Heterokontophytes and the Haptophytes, and then from these last to the Myzozoa.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.